Moreover, subgroup analysis confirmed the association between FFAR4 downregulation and poorer prognosis in patients with LUAD with T stage: T3 and T4; N stage: N0, N1, and N2; M stage: M0; pathological stage: stage I, II, and III; pathological stage: stage II; residual tumor: R0 and R1; anatomical tumor partitioning: left; and age: ≤ 65 (all P < 0.05; Fig. 2B–I). Here, FFAR4 is linked to neoplasm.